NAD+ improves cognitive function and reduces neuroinflammation by ameliorating mitochondrial damage and decreasing ROS production in chronic cerebral hypoperfusion models through Sirt1/PGC-1α pathway

Background: Microglial-mediated neuroinflammation plays an important role in vascular dementia, and modulating neuroinflammation has emerged as a promising treatment target. Nicotinamide adenine dinucleotide (NAD(+)) shows anti-inflammatory and anti-oxidant effects in many neurodegenerative disease models, but its role in the chronic cerebral hypoperfusion (CCH) is still unclear. Methods: The bilateral common carotid artery occlusion (BCCAO) was performed to establish CCH models in Sprague-Dawley rats. The rats were given daily intraperitoneal injection of NAD(+) for 8 weeks. The behavioral test and markers for neuronal death and neuroinflammation were analyzed. Mitochondrial damage and ROS production in microglia were also assessed. RNA-seq was performed to investigate the mechanistic pathway changes. For in vitro studies, Sirt1 was overexpressed in BV2 microglial cells to compare with NAD(+) treatment effects on mitochondrial injury and neuroinflammation. Results: NAD(+) administration rescued cognitive deficits and inhibited neuroinflammation by protecting mitochondria and decreasing ROS production in CCH rats. Results of mechanistic pathway analysis indicated that the detrimental effects of CCH might be associated with decreased gene expression of PPAR-gamma co-activator1 alpha (PGC-1 alpha) and its upstream transcription factor Sirt1, while NAD(+) treatment markedly reversed their decrease. In vitro study confirmed that NAD(+) administration had protective effects on hypoxia-induced neuroinflammation and mitochondrial damage, as well as ROS production in BV2 microglia via Sirt1/PGC-1 alpha pathway. Sirt1 overexpression mimicked the protective effects of NAD(+) treatment in BV2 microglia. Conclusions: NAD(+) ameliorated cognitive impairment and dampened neuroinflammation in CCH models in vivo and in vitro, and these beneficial effects were associated with mitochondrial protection and ROS inhibition via activating Sirt1/PGC-1 alpha pathway.

Automated summary

NAD(+) administration showed protective effects on cognitive impairment and neuroinflammation in chronic cerebral hypoperfusion models in vivo and in vitro, by activating the Sirt1/PGC-1 alpha pathway for mitochondrial protection and ROS inhibition.